drugset / Trial / NCT05849207
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
NaSequentialOpen-labelTreatment
Summary
The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged \>/= 65 years with hematologic malignancies.
Timeline
- Start
- 2023-10-24
- Primary completion
- 2027-07-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 25 mg/kg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 32 mg/kg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 40 mg/kg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg/kg | Intravenous |